PTC Therapeutics prices USD 500 million 0% convertible senior notes due 2031

PTC Therapeutics, Inc.

PTCT

0.00

PTC Therapeutics priced USD 500 million of 0% Convertible Senior Notes due 2031 in a Rule 144A private placement.
Initial purchasers hold a 13-day option to buy up to an additional USD 50 million, lifting potential total issuance to USD 550 million.
Net proceeds estimated at USD 486.8 million, or USD 535.5 million if the option is fully exercised.
Proceeds earmarked to refinance 2026 convertibles, including about USD 328.8 million cash to repurchase USD 222 million principal amount in concurrent transactions.
Notes carry a USD 107.48 conversion price, a 40% premium to the June 15 close of USD 76.77.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606152314PR_NEWS_USPR_____NY84566) on June 16, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.